AP NEWS
Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Oxford Nanopore Prevails in Patent Ruling against Pacific Biosciences

January 22, 2019 GMT

OXFORD, England--(BUSINESS WIRE)--Jan 22, 2019--Today the European Patent Office revoked Pacific Biosciences patent EP3045542 with claims to a single molecule sequencing process wherein two strands of DNA are linked by a connecting nucleic acid. The validity of the patent had been challenged by Oxford Nanopore.

The EPO ruled that the claims to a single molecule sequencing process were unsupported in the application and that the application only supported a template-directed synthesis sequencing method. As Pacific Biosciences were unwilling to accept this change, the patent was revoked.

The decision by the EPO is consistent with a recent decision by the International Trade Commission (ITC) to limit the claims of a related Pacific Biosciences US patent to template-directed synthesis.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190122005733/en/

CONTACT: Oxford Nanopore

Zoe McDougall

media@nanoporetech.com

Website: https://nanoporetech.com/

KEYWORD: UNITED KINGDOM EUROPE

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Oxford Nanopore

Copyright Business Wire 2019.

PUB: 01/22/2019 12:04 PM/DISC: 01/22/2019 12:04 PM

http://www.businesswire.com/news/home/20190122005733/en